Physician profile
Janet Ogletree
NPI 1053464172
$3,120.68
in general payments reported to CMS, 2019-2025
18 companies · $667 in 2025
The $667 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $249 · 2021: $57.94 · 2022: $288 · 2023: $264 · 2024: $908 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.30 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $617.33 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $446.78 | 2019-2025 | Total30, Precision 1, Precision7 |
| Biotissue Holdings INC. | $382.63 | 2024-2025 | |
| Johnson & Johnson Vision Care, INC. | $289.69 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $280.47 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $254.66 | 2022-2025 | Infuse |
| Sun Pharmaceutical Industries INC. | $235.29 | 2019-2025 | |
| Shire North American Group INC | $125.79 | 2019 | |
| Dompe US, INC. | $121.77 | 2025 | Oxervate |
| Allergan, INC. | $93.84 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $49.81 | 2024-2025 | Xdemvy |
| Optos, INC. | $49.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $49.44 | 2020-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $47.92 | 2022 | |
| Abbvie INC. | $24.05 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Oyster Point Pharma, INC. | $14.97 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Ogletree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.